Skip to Content
Manchester Metropolitan University Library
The molecular pathology of neurodegenerative disease

The molecular pathology of neurodegenerative disease

Lewis, Patrick A., author; Spillane, Jennifer E., author

The Molecular and Clinical Pathology of Neurodegenerative Disease brings together in one volume our current understanding of the molecular basis of neurodegeneration in humans, targeted at neuroscientists and graduate students in neuroscience, and the biomedical and biological sciences. Bringing together up-to-date molecular biology data with clinical evidence, this book sheds a light on common molecular mechanisms that underlie many different neurodegenerative diseases and addresses the molecular pathologies in each. The combined research and clinical background of the authors provides a unique perspective in relating clinical experiences with the molecular understanding needed to examine these diseases and is a must-read for anyone who wants to learn more about neurodegeneration

eBook, Electronic resource, Book. English. Electronic books.
Published London : Academic Press 2018

This resource is available electronically from the following locations

Details

Statement of responsibility: Patrick A. Lewis, Jennifer E. Spillane
ISBN: 0128110708, 9780128110690, 9780128110706
Note: Print version record.
Note: Includes bibliographical references and index.
Physical Description: 1 online resource : illustrations
Subject: Nervous system Diseases Pathophysiology.; Nervous system Degeneration.; HEALTH & FITNESS / Diseases / General; MEDICAL / Diseases; MEDICAL / Internal Medicine; MEDICAL / Clinical Medicine; MEDICAL / Evidence-Based Medicine

Contents

  1. Front Cover; The Molecular and Clinical Pathology of Neurodegenerative Disease; The Molecular and Clinical Pathology of Neurodegenerative Disease; Copyright; Contents; Preface; Acknowledgments; 1
  2. AN INTRODUCTION TO NEURODEGENERATION; 1.1 WHAT IS NEURODEGENERATION?; 1.2 HOW TO USE THIS TEXTBOOK; 1.3 THE FUNDAMENTALS OF NEUROANATOMY; 1.4 A BEGINNER'S GUIDE TO BRAIN CELLS; 1.5 CLINICAL TOOLS; 1.6 METHODS AND MODELS FOR INVESTIGATING NEURODEGENERATION; 1.7 DRUGS, DRUG DEVELOPMENT, AND CLINICAL TRIALS; 1.8 SUMMARY; FURTHER READING; REFERENCES; 2
  3. ALZHEIMER'S DISEASE AND DEMENTIA
  4. 2.1 INTRODUCTION2.2 CLINICAL PRESENTATION
  5. 2.2.1 ALZHEIMER'S DISEASE
  6. 2.2.2 VASCULAR DEMENTIA
  7. 2.2.3 POSTERIOR CORTICAL ATROPHY
  8. 2.2.4 LOGOPENIC APHASIA
  9. 2.2.5 DYSEXECUTIVE OR FRONTAL VARIANT
  10. 2.2.6 DIAGNOSIS OF ALZHEIMER'S DISEASE
  11. 2.2.7 MANAGEMENT
  12. 2.2.8 FRONTOTEMPORAL DEMENTIA
  13. 2.2.9 BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA
  14. 2.2.10 LANGUAGE VARIANT
  15. 2.2.11 DOWN SYNDROME AND TRISOMY 21
  16. 2.2.12 DEMENTIA WITH LEWY BODIES
  17. 2.2.13 CHRONIC TRAUMATIC ENCEPHALOPATHY
  18. 2.2.14 OTHER DEMENTIA SYNDROMES
  19. 2.3 PATHOLOGY
  20. 2.3.1 NEURONAL LOSS
  21. 2.3.2 AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES
  22. 2.3.3 LEWY BODIES2.3.4 GLIAL PATHOLOGY
  23. 2.3.5 TAUOPATHIES
  24. 2.3.6 OTHER PATHOLOGIES
  25. 2.4 MOLECULAR MECHANISMS OF DEGENERATION
  26. 2.4.1 NEUROGENETICS
  27. 2.4.1.1 Mendelian Forms of Alzheimer's-APP, PSEN1, PSEN2
  28. 2.4.1.2 Other Mendelian Genes
  29. 2.4.1.3 Risk Factors
  30. 2.4.2 ANIMAL AND CELLULAR MODELS FOR DISEASE
  31. 2.4.3 PROTEIN AGGREGATION AND DISEASE
  32. 2.4.4 THE AMYLOID CASCADE
  33. 2.4.5 MOLECULAR MECHANISMS DRIVING NEURODEGENERATION
  34. 2.4.6 PROTEIN AGGREGATE SPREAD
  35. 2.4.7 NEUROINFLAMMATION AND IMMUNE RESPONSE
  36. 2.4.8 INTERPLAY BETWEEN GENETICS, PATHOLOGY, AGING, AND SPORADIC DISEASE
  37. 2.5 THERAPIES
  38. 2.5.1 EXISTING THERAPIES2.5.2 DRUG DISCOVERY; 2.5.2.1 Targeting Amyloid Beta Production; 2.5.2.2 Removing Amyloid Beta; 2.5.3 TARGETING TAU; 2.5.4 INTERVENING IN NEUROINFLAMMATION AND THE IMMUNE RESPONSE; 2.5.5 OTHER STRATEGIES; 2.5.6 WHY ARE DRUGS FAILING?; 2.6 CONCLUSIONS; REFERENCES; 3
  39. PARKINSON'S DISEASE; 3.1 INTRODUCTION; 3.2 CLINICAL PRESENTATION; 3.2.1 MOTOR SYMPTOMS; 3.2.2 NONMOTOR SYMPTOMS; 3.2.2.1 Neuropsychiatric; 3.2.2.2 Autonomic; 3.2.2.3 Sleep Disturbance; 3.2.2.4 Sensory; 3.2.2.5 Anosmia; 3.2.3 DEMENTIA AND PARKINSON'S DISEASE; 3.2.4 PROGRESSION/PROGNOSIS
  40. 3.2.5 PROGRESSIVE SUPRANUCLEAR PALSY AND MULTIPLE SYSTEM ATROPHY3.2.5.1 Progressive Supranuclear Palsy
  41. 3.2.5.2 Multiple System Atrophy
  42. 3.3 PATHOLOGY
  43. 3.3.1 NIGRAL DEGENERATION
  44. 3.3.2 LEWY BODIES
  45. 3.3.4 DOPAMINERGIC NETWORKS
  46. 3.3.5 BEYOND THE SUBSTANTIA NIGRA
  47. 3.3.6 BEYOND LEWY BODIES
  48. 3.4 MOLECULAR MECHANISMS OF DEGENERATION
  49. 3.4.1 GENETICS
  50. 3.4.1.1 Protein Aggregation/Proteostasis
  51. 3.4.1.2 Mitochondrial Dysfunction
  52. 3.4.1.3 Inflammation
  53. 3.4.2 ENVIRONMENTAL ROUTES TO PARKINSONISM
  54. 3.4.2.1 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
  55. 3.4.2.2 Rotenone and Paraquat